,

BCI Pharma is delighted to share its latest results from three preclinical oncology studies

BCI Pharma, in collaboration with Mithra Women’s Health, has demonstrated the anti-tumor activity of its CSF1R inhibitors in several cancer models. Significant tumor regression was observed either alone or in combination with a checkpoint inhibitor leading to a complete sustained tumor regression in 50% of the animals in a triple negative breast cancer model, a very aggressive form of breast cancer. These compelling results demonstrate the huge potential of BCI CSF1R inhibitors in cancer and reinforce the partnership between the two companies.

Follow the link to read Mithra’s press release

/by
,

BCI Pharma is thrilled to announce positive preclinical results for its CSF1R inhibitors

BCI Pharma is delighted to announce preclinical studies confirmed the broad therapeutic potential of its CSF1R inhibitors. These meaningful and compelling preclinical data come from a fruitful partnership with Mithra Women’s Health and cover medical areas for which unsatisfied therapeutic needs persist including cancer, endometriosis and inflammatory disorders.

Follow the link to read Mithra’s press release.

/by

BCI Pharma will present a poster at the XXVII EFMC International Symposium on Medicinal Chemistry

EFMC-ISCM 2022BCI Pharma will attend the XXVII EFMC International Symposium on Medicinal Chemistry in Nice from September 4-8, 2022 and present its promising research program targeting tumor-associated macrophages. Mode of action and efficacy data of its preclinical candidate will be discussed.

/by

BCI Pharma will present a poster at the 17th Annual meeting GSO in Carcassonne (France)

GSO congrès

BCI Pharma will present its promising research program targeting tumor-associated macrophages. Mode of action and efficacy data of its preclinical candidate will be discussed.

/by

BCI Pharma will participate in the digital 26th annual Bio-Europe

Bio-Europe 2020

BCI Pharma will discuss with pharmas and investors on their promising research projects.

/by

BCI Pharma will attend the 25th annual Bio-Europe in Hamburg (Germany)

bio-europe 2019

BCI Pharma will attend great strategic discussions on its neuropathic pain project.

/by

BCI Pharma will give a talk on its great neuropathic pain project

BCI Pharma has been invited to give a lecture during the pain session at the EFMC symposium in Krakow (Poland). Great in vivo efficacy data will be presented.

/by

BCI Pharma will present two posters on their research projects on neuropathic pain

BCI Pharma will participate in the 7th International Congress on Neuropathic pain in London (United Kingdom) and will be presented their research programs on this field.

/by

BCI Pharma will give a talk on its best-in-class peripheral neuropathic drug

The talk will be given during the Annual One-day Meeting on Medicinal Chemistry of SRC &KVCV in Namur (Belgium). Great in vivo efficacy data will be presented.

/by

BCI Pharma will attend the 24th annual Bio-Europe in Copenhagen (Danemark)

BCI Pharma will attend great strategic discussions on their research projects.

/by